127 related articles for article (PubMed ID: 38129136)
1. Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Lorusso D; Mouret-Reynier MA; Harter P; Cropet C; Caballero C; Wolfrum-Ristau P; Satoh T; Vergote I; Parma G; Nøttrup TJ; Lebreton C; Fasching PA; Pisano C; Manso L; Bourgeois H; Runnebaum I; Zamagni C; Hardy-Bessard AC; Schnelzer A; Fabbro M; Schmalfeldt B; Berton D; Belau A; Lotz JP; Gropp-Meier M; Gladieff L; Lück HJ; Abadie-Lacourtoisie S; Pujade-Lauraine E; Ray-Coquard I
Int J Gynecol Cancer; 2024 Apr; 34(4):550-558. PubMed ID: 38129136
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Harter P; Mouret-Reynier MA; Pignata S; Cropet C; González-Martín A; Bogner G; Fujiwara K; Vergote I; Colombo N; Nøttrup TJ; Floquet A; El-Balat A; Scambia G; Guerra Alia EM; Fabbro M; Schmalfeldt B; Hardy-Bessard AC; Runnebaum I; Pujade-Lauraine E; Ray-Coquard I
Gynecol Oncol; 2022 Feb; 164(2):254-264. PubMed ID: 34952708
[TBL] [Abstract][Full Text] [Related]
3. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
Ray-Coquard I; Leary A; Pignata S; Cropet C; González-Martín A; Marth C; Nagao S; Vergote I; Colombo N; Mäenpää J; Selle F; Sehouli J; Lorusso D; Guerra Alia EM; Bogner G; Yoshida H; Lefeuvre-Plesse C; Buderath P; Mosconi AM; Lortholary A; Burges A; Medioni J; El-Balat A; Rodrigues M; Park-Simon TW; Dubot C; Denschlag D; You B; Pujade-Lauraine E; Harter P;
Ann Oncol; 2023 Aug; 34(8):681-692. PubMed ID: 37211045
[TBL] [Abstract][Full Text] [Related]
4. Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial.
Fujiwara K; Fujiwara H; Yoshida H; Satoh T; Yonemori K; Nagao S; Matsumoto T; Kobayashi H; Bourgeois H; Harter P; Mosconi AM; Vazquez IP; Reinthaller A; Fujita T; Rowe P; Pujade-Lauraine E; Ray-Coquard I
J Gynecol Oncol; 2021 Sep; 32(5):e82. PubMed ID: 34378365
[TBL] [Abstract][Full Text] [Related]
5. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.
González-Martín A; Desauw C; Heitz F; Cropet C; Gargiulo P; Berger R; Ochi H; Vergote I; Colombo N; Mirza MR; Tazi Y; Canzler U; Zamagni C; Guerra-Alia EM; Levaché CB; Marmé F; Bazan F; de Gregorio N; Dohollou N; Fasching PA; Scambia G; Rubio-Pérez MJ; Milenkova T; Costan C; Pautier P; Ray-Coquard I;
Eur J Cancer; 2022 Oct; 174():221-231. PubMed ID: 36067615
[TBL] [Abstract][Full Text] [Related]
6. Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
Pujade-Lauraine E; Brown J; Barnicle A; Wessen J; Lao-Sirieix P; Criscione SW; du Bois A; Lorusso D; Romero I; Petru E; Yoshida H; Vergote I; Colombo N; Hietanen S; Provansal M; Schmalfeldt B; Pignata S; Martín Lorente C; Berton D; Runnebaum IB; Ray-Coquard I
JCO Precis Oncol; 2023 Jan; 7():e2200258. PubMed ID: 36716415
[TBL] [Abstract][Full Text] [Related]
7. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I; Pautier P; Pignata S; Pérol D; González-Martín A; Berger R; Fujiwara K; Vergote I; Colombo N; Mäenpää J; Selle F; Sehouli J; Lorusso D; Guerra Alía EM; Reinthaller A; Nagao S; Lefeuvre-Plesse C; Canzler U; Scambia G; Lortholary A; Marmé F; Combe P; de Gregorio N; Rodrigues M; Buderath P; Dubot C; Burges A; You B; Pujade-Lauraine E; Harter P;
N Engl J Med; 2019 Dec; 381(25):2416-2428. PubMed ID: 31851799
[TBL] [Abstract][Full Text] [Related]
8. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
Vergote I; Ray-Coquard I; Anderson DM; Cantuaria G; Colombo N; Garnier-Tixidre C; Gilbert L; Harter P; Hettle R; Lorusso D; Mäenpää J; Marth C; Matsumoto K; Ouwens M; Poveda A; Raspagliesi F; Rhodes K; Rubio Pérez MJ; Shapira-Frommer R; Shikama A; Sikorska M; Moore K; DiSilvestro P
Eur J Cancer; 2021 Nov; 157():415-423. PubMed ID: 34597975
[TBL] [Abstract][Full Text] [Related]
9. Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab
Hettle R; McCrea C; Lee CK; Davidson R
Ther Adv Med Oncol; 2021; 13():17588359211049639. PubMed ID: 34616492
[TBL] [Abstract][Full Text] [Related]
10. Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.
Paik J
Target Oncol; 2021 Nov; 16(6):847-856. PubMed ID: 34623572
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial.
Sabatier R; Rousseau F; Joly F; Cropet C; Montégut C; Frindte J; Cinieri S; Guerra Alía EM; Polterauer S; Yoshida H; Vergote I; Colombo N; Hietanen S; Largillier R; Canzler U; Gratet A; Marmé F; Favier L; Pujade-Lauraine E; Ray-Coquard I
Eur J Cancer; 2023 Mar; 181():42-52. PubMed ID: 36634389
[TBL] [Abstract][Full Text] [Related]
12. Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
Labidi-Galy SI; Rodrigues M; Sandoval JL; Kurtz JE; Heitz F; Mosconi AM; Romero I; Denison U; Nagao S; Vergote I; Parma G; Nøttrup TJ; Rouleau E; Garnier G; El-Balat A; Zamagni C; Martín-Lorente C; Pujade-Lauraine E; Fiévet A; Ray-Coquard IL
Ann Oncol; 2023 Feb; 34(2):152-162. PubMed ID: 36564284
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial.
Zhu Y; Liu K; Cao H; Zhu H
J Ovarian Res; 2023 Aug; 16(1):168. PubMed ID: 37605274
[TBL] [Abstract][Full Text] [Related]
14. Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis.
Zhu Y; Yang Q; Liu K; Cao H; Zhu H
J Gynecol Oncol; 2024 Jan; 35(1):e2. PubMed ID: 37477106
[TBL] [Abstract][Full Text] [Related]
15. Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial.
Callens C; Rodrigues M; Briaux A; Frouin E; Eeckhoutte A; Pujade-Lauraine E; Renault V; Stoppa-Lyonnet D; Bieche I; Bataillon G; Karayan-Tapon L; Rochelle T; Heitz F; Cecere SC; Pérez MJR; Grimm C; Nøttrup TJ; Colombo N; Vergote I; Yonemori K; Ray-Coquard I; Stern MH; Popova T
Oncogene; 2023 Nov; 42(48):3556-3563. PubMed ID: 37945748
[TBL] [Abstract][Full Text] [Related]
16. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
Arora S; Balasubramaniam S; Zhang H; Berman T; Narayan P; Suzman D; Bloomquist E; Tang S; Gong Y; Sridhara R; Turcu FR; Chatterjee D; Saritas-Yildirim B; Ghosh S; Philip R; Pathak A; Gao JJ; Amiri-Kordestani L; Pazdur R; Beaver JA
Oncologist; 2021 Jan; 26(1):e164-e172. PubMed ID: 33017510
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy in the maintenance of patients with homologous recombination deficiency-positive advanced ovarian cancer after response to first-line platinum-based chemotherapy.
Cedillo S; Garí C; Aceituno S; Manso L; Cercos Lleti AC; Ventayol Bosch P; Casado A; Perez Fidalgo A
Int J Gynecol Cancer; 2023 Dec; ():. PubMed ID: 38054270
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer.
Elsea D; Fan L; Mihai A; Moustaid FE; Simmons D; Monberg M; Muston D
Pharmacoecon Open; 2022 Nov; 6(6):811-822. PubMed ID: 36036344
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial.
Loverix L; Vergote I; Busschaert P; Vanderstichele A; Venken T; Boeckx B; Harter P; Brems H; Van Nieuwenhuysen E; Pignata S; Baert T; Gonzalez-Martin A; Han S; Marth C; Neven P; Colombo N; Berteloot P; Mäenpää J; Olbrecht S; Laga T; Sablon E; Ray-Coquard I; Pujade-Lauraine E; Lambrechts D; Van Gorp T
Eur J Cancer; 2023 Jul; 188():131-139. PubMed ID: 37245441
[TBL] [Abstract][Full Text] [Related]
20. AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial.
Heitz F; Marth C; Henry S; Reuss A; Cibula D; Gaba Garcia L; Colombo N; Schmalfeld B; de Gregorio N; Wimberger P; Hasenburg A; Sehouli J; Gropp-Meier M; Schouten PC; Hahnen E; Hauke J; Polleis S; Harter P
Int J Gynecol Cancer; 2023 Dec; 33(12):1966-1969. PubMed ID: 37935524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]